Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3334488 | 0.85 | ROCK2 (0.52) | MEN1KMT2AHTR2AHTR2CMAPT | |
| SCHEMBL3336503 | 0.83 | CTSV (0.51) | HDAC8 | |
| SCHEMBL13300080 | 0.83 | CTSV (0.51) | HDAC8 | |
| SCHEMBL3329868 | 0.77 | ROCK2 (0.50) | HDAC8 | |
| SCHEMBL2302822 | 0.76 | HDAC8 (0.40) | HDAC8 | |
| SCHEMBL2302178 | 0.72 | AKT1 (0.56) | HTR2AHTR2CALDH1A1 | |
| SCHEMBL2301203 | 0.72 | AKT1 (0.56) | HTR2AHTR2CALDH1A1 | |
| SCHEMBL3332682 | 0.72 | AKT1 (0.47) | HDAC8 | |
| SCHEMBL2300062 | 0.72 | AKT1 (0.56) | HTR2AHTR2CALDH1A1 | |
| SCHEMBL1529360 | 0.71 | AKT1 (0.59) | HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338434-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-12-25 | — | — | US | claimed |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | claimed |
| EP-2134175-A1 | INHIBITORS OF AKT ACTIVITY | Smithkline Beecham Corporation (US) | 2009-12-23 | — | — | EP | claimed |
| WO-2008121786-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-09 | — | — | WO | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-113365610-A | Methods of making and delivering bisantrene formulations | 现代化制药公司 | 2021-09-07 | — | — | CN | disclosed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-8338434-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338434-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | disclosed |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | disclosed |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | disclosed |
| EP-2134175-A1 | INHIBITORS OF AKT ACTIVITY | Smithkline Beecham Corporation (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008121786-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008121786-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | HDAC8 533/4885MEN1 1908/4885KMT2A 1253/4885 |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | PI4KB, AKT3, AKT2 | HDAC8 382/4885MEN1 3489/4885KMT2A 2217/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | HDAC8 1166/4885MEN1 760/4885KMT2A 1009/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | HDAC8 533/4885MEN1 1908/4885KMT2A 1253/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | HDAC8 3881/4885MEN1 114/4885KMT2A 903/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | HDAC8 1166/4885MEN1 760/4885KMT2A 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.